Lenzen S, Mirzaie-Petri M
Institute of Pharmacology and Toxicology, University of Göttingen, Federal Republic of Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov;346(5):532-6. doi: 10.1007/BF00169009.
Alloxan inhibited aconitase with a half maximal inhibitory concentration of 0.5 mM in sonically disrupted and 2.3 mM in intact isolated liver mitochondria. For dialuric acid the half maximal inhibitory concentrations were 1.1 mM and 2.5 mM, respectively. Ninhydrin and N-ethylmaleimide (NEM) also inhibited aconitase with half maximal inhibitory concentrations in the submillimolar range and t-butylhydroperoxide (BuOOH) in the millimolar range, which, however, were not different for disrupted and intact mitochondria. Only the aconitase substrate citrate, but not glucose provided protection of the enzyme against inhibition. In intact liver cells the half maximal inhibitory concentration for alloxan was 6.8 mM. Again, dialuric acid and BuOOH were less potent inhibitors while ninhydrin and NEM were more potent inhibitors of aconitase in intact liver cells. In intact liver cells, glucose and 3-O-methylglucose, but not mannoheptulose and citrate provided protection against alloxan inhibition. The results show that aconitase is not an enzyme particularly sensitive towards alloxan inhibition and thus apparently not a primary site for mediation of alloxan toxicity as it is the glucokinase. This makes a primary site of alloxan action in the mitochondria extremely unlikely. On the other hand the results demonstrate that both the intact mitochondrial and plasma membrane as uptake barriers provide protection against alloxan toxicity. In addition the results clearly show, that 3-O-methylglucose provides protection against alloxan action only at the level of the plasma membrane through inhibition of alloxan uptake into the cell, while the site of protection of mannoheptulose is only the sugar binding site of the glucokinase. In contrast, glucose is shown here to be the only sugar with a dual protective effect both through inhibition of alloxan uptake through the plasma membrane like 3-O-methylglucose and through protection of the glucokinase sugar binding site against alloxan inhibition of the enzyme like mannoheptulose. In the light of these results the unique protective potency of glucose as compared to that of other sugars is not surprising.
四氧嘧啶抑制乌头酸酶,在超声破碎的肝脏线粒体中其半数最大抑制浓度为0.5 mM,在完整分离的肝脏线粒体中为2.3 mM。对于二羟脲酸,半数最大抑制浓度分别为1.1 mM和2.5 mM。茚三酮和N - 乙基马来酰亚胺(NEM)也抑制乌头酸酶,其半数最大抑制浓度在亚毫摩尔范围内,叔丁基过氧化氢(BuOOH)在毫摩尔范围内,不过,对于破碎和完整的线粒体而言并无差异。只有乌头酸酶的底物柠檬酸能保护该酶免受抑制,而葡萄糖则不能。在完整的肝细胞中,四氧嘧啶的半数最大抑制浓度为6.8 mM。同样,二羟脲酸和BuOOH的抑制作用较弱,而茚三酮和NEM在完整肝细胞中对乌头酸酶的抑制作用更强。在完整的肝细胞中,葡萄糖和3 - O - 甲基葡萄糖能保护细胞免受四氧嘧啶的抑制,而甘露庚酮糖和柠檬酸则不能。结果表明,乌头酸酶并非对四氧嘧啶抑制特别敏感的酶,因此显然不像葡萄糖激酶那样是四氧嘧啶毒性介导的主要位点。这使得四氧嘧啶在线粒体中的作用位点极不可能是主要位点。另一方面,结果表明完整的线粒体膜和质膜作为摄取屏障都能提供对四氧嘧啶毒性的保护。此外,结果清楚地表明,3 - O - 甲基葡萄糖仅通过抑制四氧嘧啶进入细胞,在质膜水平提供对四氧嘧啶作用的保护,而甘露庚酮糖的保护位点仅是葡萄糖激酶的糖结合位点。相比之下,此处显示葡萄糖是唯一具有双重保护作用的糖,既像3 - O - 甲基葡萄糖那样通过抑制四氧嘧啶通过质膜的摄取,又像甘露庚酮糖那样通过保护葡萄糖激酶的糖结合位点免受四氧嘧啶对该酶的抑制。鉴于这些结果,葡萄糖与其他糖类相比具有独特的保护效力也就不足为奇了。